Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

被引:0
|
作者
José Trigo
Mónica García-Cosío
Almudena García-Castaño
Montserrat Gomà
Ricard Mesia-Nin
Elena Ruiz-Bravo
Ainara Soria-Rivas
Paola Castillo
Irene Braña-García
Margarita Alberola-Ferranti
机构
[1] HC Marbella International Hospital,
[2] Spanish Society of Medical Oncology (SEOM),undefined
[3] Ramón y Cajal University Hospital,undefined
[4] Spanish Society of Pathological Anatomy (SEAP),undefined
[5] Marqués de Valdecilla University Hospital,undefined
[6] Spanish Society of Medical Oncology (SEOM),undefined
[7] Bellvitge University Hospital,undefined
[8] Spanish Society of Pathological Anatomy (SEAP),undefined
[9] Catalan Institute of Oncology (ICO),undefined
[10] Badalona Applied Research Group in Oncology,undefined
[11] Germans Trias i Pujol Research Institute,undefined
[12] Spanish Society of Medical Oncology (SEOM),undefined
[13] La Paz University Hospital,undefined
[14] Spanish Society of Pathological Anatomy (SEAP),undefined
[15] Ramón y Cajal University Hospital,undefined
[16] Spanish Society of Medical Oncology (SEOM),undefined
[17] Clínic de Barcelona Hospital,undefined
[18] Spanish Society of Pathological Anatomy (SEAP),undefined
[19] Vall d’Hebron University Hospital,undefined
[20] Spanish Society of Medical Oncology (SEOM),undefined
[21] Vall d’Hebron University Hospital,undefined
[22] Spanish Society of Pathological Anatomy (SEAP),undefined
来源
Clinical and Translational Oncology | 2022年 / 24卷
关键词
PD-L1; Prognosis; Individualized therapy; Response to treatment; Epstein Barr virus; Human papillomavirus;
D O I
暂无
中图分类号
学科分类号
摘要
The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.
引用
收藏
页码:1890 / 1902
页数:12
相关论文
共 50 条
  • [41] Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
    Albanell, Joan
    Andreu, Xavier
    Jose Calasanz, Maria
    Concha, Angel
    Maria Corominas, Jose
    Garcia-Caballero, Tomas
    Antonio Lopez, Jose
    Lopez-Rios, Fernando
    Ramon y Cajal, Santiago
    Vera-Sempere, Francisco J.
    Colomer, Ramon
    Martin, Miguel
    Alba, Emilio
    Gonzalez-Martin, Antonio
    Llombart, Antonio
    Lluch, Ana
    Palacios, Jose
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (06): : 363 - 375
  • [42] Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
    Goday, A.
    Barneto, I.
    Garcia-Almeida, J. M.
    Blasco, A.
    Lecube, A.
    Gravalos, C.
    Martinez de Icaya, P.
    de las Penas, R.
    Monereo, S.
    Vazquez, L.
    Palacio, J. E.
    Perez-Segura, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (10): : 763 - 771
  • [43] Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer
    Quintanar, T.
    Font, C.
    Gallardo, E.
    Barba, R.
    Obispo, B.
    Diaz-Pedroche, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (04): : 697 - 708
  • [44] Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer
    T. Quintanar
    C. Font
    E. Gallardo
    R. Barba
    B. Obispo
    C. Díaz-Pedroche
    Clinical and Translational Oncology, 2021, 23 : 697 - 708
  • [45] Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
    A. Goday
    I. Barneto
    J. M. García-Almeida
    A. Blasco
    A. Lecube
    C. Grávalos
    P. Martínez de Icaya
    R. de las Peñas
    S. Monereo
    L. Vázquez
    J. E. Palacio
    P. Pérez-Segura
    Clinical and Translational Oncology, 2015, 17 : 763 - 771
  • [46] Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
    Gomez-Martin, Carlos
    Concha, Angel
    Mara Corominas, Jose
    Garcia-Caballero, Tomas
    Garcia-Garcia, Elena
    Iglesias, Mar
    Antonio Lopez, Jose
    Ramon y Cajal, Santiago
    Rojo, Federico
    Palacios, Jose
    Vera-Sempere, Francisco
    Aranda, Enrique
    Colomer, Ramon
    Garcia-Alfonso, Pilar
    Garrido, Pilar
    Rivera, Fernando
    Lopez-Rios, Fernando
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (09): : 636 - 651
  • [47] Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
    Carlos Gómez-Martín
    Ángel Concha
    José María Corominas
    Tomás García-Caballero
    Elena García-García
    Mar Iglesias
    José Antonio López
    Santiago Ramón y Cajal
    Federico Rojo
    José Palacios
    Francisco Vera-Sempere
    Enrique Aranda
    Ramon Colomer
    Pilar García-Alfonso
    Pilar Garrido
    Fernando Rivera
    Fernando López-Ríos
    Clinical and Translational Oncology, 2011, 13 : 636 - 651
  • [48] Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
    P. Pérez-Segura
    J. E. Palacio
    L. Vázquez
    S. Monereo
    R. de las Peñas
    P. Martínez de Icaya
    C. Grávalos
    A. Lecube
    A. Blasco
    J. M. García-Almeida
    I. Barneto
    A. Goday
    Clinical and Translational Oncology, 2017, 19 : 682 - 694
  • [49] Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
    Perez-Segura, P.
    Palacio, J. E.
    Vazquez, L.
    Monereo, S.
    de las Penas, R.
    Martinez de Icaya, P.
    Gravalos, C.
    Lecube, A.
    Blasco, A.
    Garcia-Almeida, J. M.
    Barneto, I.
    Goday, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 682 - 694
  • [50] Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
    Pilar García-Alfonso
    Ramón Salazar
    Jesús García-Foncillas
    Eva Musulén
    Rocío García-Carbonero
    Artemio Payá
    Pedro Pérez-Segura
    Santiago Ramón y Cajal
    Samuel Navarro
    Clinical and Translational Oncology, 2012, 14 : 726 - 739